BridgeMD
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA).
EU CTIS ID: 2023-507031-38-00
What this study is testing
To evaluate the effect of tozorakimab versus placebo as add on to SoC in participants with viral lung infection requiring supplemental oxygen on the prevention of death or progression to IMV/ECMO by Day 28
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Adult participants ≥ 18 years old at the time of signing the informed consent form.
- 2. Patients hospitalised with viral lung infection.
- 3. Hypoxaemia requiring treatment with supplemental O2. Hypoxaemia is defined as: SpO2 ≤ 90% OR SpO2 ≤ 92% AND one or both of the following: Radiographic infiltrates by CXR/CT compatible with viral lung infection per investigator judgement. Use of accessory muscles of respiration or RR > 22.
- 4. Patient remains hypoxaemic at randomisation requiring treatment with supplemental oxygen.
You likely can't join if
- 1. Known fungal or parasitic lung infection, aspiration lung infection, lung abscess, or evidence of septic shock. Bacterial co-infection is allowed, unless, in the opinion of the investigator, bacterial infection defines the severity of the participant’s condition.
- 2. Hypoxaemia caused primarily by extrapulmonary insult or by lung injury of non-infective aetiology.
- 3. Ongoing IMV/ECMO at randomisation.
- 4. The following malignancies: - Solid tumours with metastases (Stage IV). - Lymphoma/leukaemia not in complete remission. - Malignancies treated with chemotherapy and/or immunomodulatory drugs within the past 2 months.
The study team makes the final eligibility decision.
Where it's taking place
- Australia
- India
- China
- Japan
- Taiwan
- Israel
- Mexico
- Canada
- Saudi Arabia
- Thailand
- Vietnam
- South Africa
- United Kingdom
- Philippines
- Hong Kong
- Colombia
- Malaysia
- Peru
- Argentina
- United States
+ 2 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Australia; India; China; Japan; Taiwan; Israel and 16 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.